

Aubagne, July 21, 2023

## Information on Document Availability

The report on the first half 2023 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: <https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations>

It contains the following information:

- Business development for the period of January to June 2023 as well as the 2023 full year forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2023

### **A profile of Sartorius Stedim Biotech**

. Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In fiscal 2022, the company generated sales revenue of around 3.5 billion euros. At the end of 2022, around 12,000 employees were working for customers around the globe.

### **Contact**

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

petra.mueller2@sartorius.com